Company news

TuHURA Biosciences, Inc. news in 2025

TuHURA Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

December 15, 2025

TuHURA Biosciences Provides Corporate Update Following Recent Financing

December 11, 2025

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

December 9, 2025

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

December 8, 2025

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

November 14, 2025

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

November 3, 2025

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

August 20, 2025

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

August 14, 2025

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

July 1, 2025

TuHURA Biosciences Completes Acquisition of Kineta

June 30, 2025

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

June 24, 2025

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

June 23, 2025

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

June 9, 2025

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

June 3, 2025

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

June 2, 2025

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 15, 2025

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 13, 2025

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

May 5, 2025

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

April 28, 2025

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

April 8, 2025

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

April 7, 2025

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

April 1, 2025

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

March 11, 2025

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

March 10, 2025

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

February 19, 2025

Decks in 2025